Gabapentin for fibromyalgia pain in adults (Q24185818)

https://api.crossref.org/works/10.1002%2F14651858.CD012188

Gabapentin in acute postoperative pain management

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD012188

Interpreting the clinical importance of treatment outcomes in chronic pain clinical trials: IMMPACT recommendations

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD012188

Gabapentin receptor alpha2delta-1 is a neuronal thrombospondin receptor responsible for excitatory CNS synaptogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD012188

How do changes in pain severity levels correspond to changes in health status and function in patients with painful diabetic peripheral neuropathy?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD012188

Assessing the quality of reports of randomized clinical trials: is blinding necessary?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD012188

Drugs for neuropathic pain.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD012188

Fibromyalgia and neuropathic pain--differences and similarities. A comparison of 3057 patients with diabetic painful neuropathy and fibromyalgia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD012188

Meta-analysis in clinical research

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD012188

The Neurontin legacy--marketing through misinformation and manipulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD012188

Duloxetine for treating painful neuropathy, chronic pain or fibromyalgia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD012188

Size is everything--large amounts of information are needed to overcome random effects in estimating direction and magnitude of treatment effects

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD012188

"Evidence" in chronic pain--establishing best practice in the reporting of systematic reviews

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD012188

Fibromyalgia: Moderate and substantial pain intensity reduction predicts improvement in other outcomes and substantial quality of life gain

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD012188

Responder analysis for pain relief and numbers needed to treat in a meta-analysis of etoricoxib osteoarthritis trials: bridging a gap between clinical trials and clinical practice

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD012188

Numbers-needed-to-treat analyses--do timing, dropouts, and outcome matter? Pooled analysis of two randomized, placebo-controlled chronic low back pain trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD012188

Minimum efficacy criteria for comparisons between treatments using individual patient meta-analysis of acute pain trials: examples of etoricoxib, paracetamol, ibuprofen, and ibuprofen/paracetamol combinations after third molar extraction

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD012188

Mean analgesic consumption is inappropriate for testing analgesic efficacy in post-operative pain: analysis and alternative suggestion

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD012188

Amitriptyline for neuropathic pain and fibromyalgia in adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD012188

Estimate at your peril: imputation methods for patient withdrawal can bias efficacy outcomes in chronic pain trials using responder analyses

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD012188

Pain measures and cut-offs - 'no worse than mild pain' as a simple, universal outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD012188

Expect analgesic failure; pursue analgesic success

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD012188

The costs and consequences of adequately managed chronic non-cancer pain and chronic neuropathic pain

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD012188

Duloxetine use in chronic painful conditions--individual patient data responder analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD012188

Worldwide epidemiology of fibromyalgia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD012188

Gastroretentive gabapentin (G-GR) formulation reduces intensity of pain associated with postherpetic neuralgia (PHN).

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD012188

Resting state connectivity correlates with drug and placebo response in fibromyalgia patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD012188

Enriched enrollment: definition and effects of enrichment and dose in trials of pregabalin and gabapentin in neuropathic pain. A systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD012188

Pregabalin in fibromyalgia--responder analysis from individual patient data

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD012188

Interference with work in fibromyalgia: effect of treatment with pregabalin and relation to pain response

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD012188

Duloxetine for painful diabetic neuropathy and fibromyalgia pain: systematic review of randomised trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD012188

Outcome reporting in industry-sponsored trials of gabapentin for off-label use

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD012188

Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990–2010: a systematic analysis for the Global Burden of Disease Study 2010

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD012188

Anticonvulsant drugs for acute and chronic pain.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD012188

The American College of Rheumatology 1990 Criteria for the Classification of Fibromyalgia. Report of the Multicenter Criteria Committee

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD012188

The American College of Rheumatology preliminary diagnostic criteria for fibromyalgia and measurement of symptom severity

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD012188

Fibromyalgia prevalence, somatic symptom reporting, and the dimensionality of polysymptomatic distress: results from a survey of the general population.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD012188

What is fibromyalgia, how is it diagnosed, and what does it really mean?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD012188

Gabapentin for chronic neuropathic pain in adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD012188

7 January 2021

Antiepileptic drugs for neuropathic pain and fibromyalgia

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD012188

7 January 2021

The effect of a combination of gabapentin and donepezil in an experimental pain model in healthy volunteers: Results of a randomized controlled trial

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD012188

7 January 2021

Patient-centered perspective on treatment outcomes in chronic pain

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD012188

7 January 2021